Hepatic carcinoma
Conditions
Interventions
DC-CIK immunotherapy Group:DC-CIK immunotherapy after hepatectomy
hepatectomy group :hepatectomy
Sponsors
Mengchao Hepatobiliary Hospital of Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients aged 18 to 80 years, No gender limitation. 2.To be diagnosed with resectable hepatocellar carcinoma by clinicopathology, and the BCLC stage is A or B. No residual tumor and no metastatic or recurrence tumor were found by CT or MRI scanning after hepatectomy for four weeks. 3.Patients with expected survival more than 6 months. 4.The score of Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1; 5.The hematopoietic function of bone marrow should be normal:White blood cell(WBC)> 4.0×10^9/L, platelet (PLT)> 100×10^9/L, hemoglobin (Hb)>120 g/L; 6. Fertile female patients should be excluded from pregnancy, and HCG must be negative;both male and female subjects should Use contraception during the study. 7.The patients volunteer to join in the trial and sign the informed consents.
Exclusion criteria
Exclusion criteria: 1) Combined with other primary malignant tumors; 2) Bone marrow or organ transplantation history; Gastrointestinal bleeding tendency;Coagulation dysfunction; Or thrombotic diseases; 3) Autoimmune deficiency disease;Infection by various virus which do not under control (including HAV, HCV, HDV, etc.); 4) Suffering from other severe systemic diseases, including severe respiratory, circulatory, neurological, mental, digestive, endocrine, immune and urinary diseases, The factors may interfere with the treatment evaluation and compliance of this study; Or biochemical indicators: serum bilirubin (TBILI) > 1.5 * ULN ( The upper limit of the normal reference values), ALT and AST >2.5*ULN,Serum creatinine (Cr)> 2*ULN. 5) Pregnant or nursing women; Disabilities patients by law (blind, deaf, dumb, mentally retarded, physically disabled) or Mental diseases;Taking drugs or Adverse drug abuse and alcohol dependence within 5 years; 6) Participating in or participated in other clinical trials within one month; 7) The investigator judges that the patient is not fit for this study due to any factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;OS; | — |
Secondary
| Measure | Time frame |
|---|---|
| QOL;Safety; | — |
Countries
China
Contacts
Public ContactXiaolou Li
Outcome results
None listed